ATR-258

ID: atr258

Aliases: ATR258

Type: compound

Route/form: oral investigational drug

Status: investigational

Evidence level: early human

Best data tier: early human + investigational

Support scope: human, context

Source types: early_human, institutional_summary

Linked sources: 2

Broad outcomes: Fat loss / metabolic health, Muscle growth / performance / recovery

Reading note: These are curation notes anchored to linked sources, not a clinical recommendation or protocol.

Targets / mechanism

• beta-2 adrenergic agonism
• metabolic disease program

Optimization domains

• muscle hypertrophy
• obesity
• type 2 diabetes
• investigational drug

Research basis

• A Cell paper describes ATR-258/compound 15 as a GRK2-biased beta-2 adrenergic agonist with skeletal-muscle glucose uptake, metabolic preclinical data, and first-in-human context.
• Worth tracking because it bridges obesity pharmacology and lean-mass preservation claims.

Limits, risks, and missing evidence

• The human component is still early and does not establish phase 2 efficacy, durability, or long-term safety.
• Beta-adrenergic mechanisms require cardiovascular and tolerability scrutiny even when bias is proposed to reduce liabilities.

Risk flags

• investigational
• limited public data
• cardiovascular monitoring
• beta adrenergic
• early human not efficacy

Linked papers, labels, and reviews

1. GRK-biased adrenergic agonists for the treatment of type 2 diabetes and obesity
   early_human / sciencedirect_atr258_cell_2025
   Cell paper for ATR-258/compound 15 GRK2-biased beta-2 adrenergic mechanism, preclinical metabolic data, and first-in-human context; cardiovascular and tolerability scrutiny remain central because of the beta-2 mechanism.
2. ATR-258 oral therapy for diabetes and obesity without loss of muscle mass
   institutional_summary / monash_atr258_cell_2025
   Monash summary of Cell paper on pathway-selective beta-2 adrenergic agonism and glucose uptake.